Dulaglutide Modulates the Development of Tissue-Infiltrating Th1/Th17 Cells and the Pathogenicity of Encephalitogenic Th1 Cells in the Central Nervous System
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
GLP-1 (glucagon-like peptide-1) has been reported to play a vital role in neuroprotection. Experimental autoimmune encephalomyelitis (EAE) is a well-established animal model widely used to study human multiple sclerosis, a chronic demyelination disease in the central nervous system (CNS). Recently, important studies have designated that the signaling axis of GLP-1 and its receptor controls the clinical manifestations and pathogenesis of EAE. However, it is elusive whether GLP-1 receptor signaling regulates the phenotype of autoreactive T cells in the CNS. We administered dulaglutide, a well-established GLP-1 receptor agonist (GLP-1 RA), to treat EAE mice prophylactically or semi-therapeutically and subsequently analyzed the mononuclear cells of the CNS. In this study, dulaglutide treatment significantly alleviates the clinical manifestations and histopathological outcomes of EAE. Dulaglutide decreases incidences of encephalitogenic Th1/Th17 cells and Th1 granulocyte-macrophage-colony-stimulating factor (GM-CSF) expression in the CNS. Administration of dulaglutide failed to control the chemotactic abilities of encephalitogenic Th1 and Th17 cells; however, prophylactic treatment considerably decreased the populations of dendritic cells and macrophages in the CNS parenchyma. These results obtained indicate that dulaglutide modulates the differentiation of encephalitogenic Th1/Th17 and the pathogenicity of Th1 cells by influencing antigen presenting cells quantities, providing mechanism insight on T cells regulation in ameliorating EAE by GLP-1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McGeachy, M. J., Bak-Jensen, K. S., Chen, Y., Tato, C. M., Blumenschein, W., McClanahan, T., & Cua, D. J. (2007) · Nature Immunology · doi:10.1038/ni1539 · Cited by 1,520
Self-citationOrigin, fate and dynamics of macrophages at central nervous system interfaces
Goldmann, T., Wieghofer, P., Jordão, M. J. C., Prutek, F., Hagemeyer, N., Frenzel, K., Amann, L., Staszewski, O., Kierdorf, K., Krueger, M., et al. (2016) · Nature Immunology · doi:10.1038/ni.3423 · Cited by 1,209 · cited 1×
“DCs and macrophages are key antigen-presenting cells (APCs) during the pathogenesis of EAE [10,22,27].”
BackgroundCodarri, L., Gyülvészi, G., Tosevski, V., Hesske, L., Fontana, A., Magnenat, L., Suter, T., & Becher, B. (2011) · Nature Immunology · doi:10.1038/ni.2027 · Cited by 1,191
Fate mapping of IL-17-producing T cells in inflammatory responses
Hirota, K., Duarte, J. H., Veldhoen, M., Hornsby, E., Li, Y., Cua, D. J., Ahlfors, H., Wilhelm, C., Tolaini, M., Menzel, U., et al. (2011) · Nature Immunology · doi:10.1038/ni.1993 · Cited by 1,176 · cited 3×
“Briefly, Th1/Th17 cell is a T cell subset co-expressing IFN-γ and IL-17A that is present in CNS of EAE mice [14].”
BackgroundEl-Behi, M., Ciric, B., Dai, H., Yan, Y., Cullimore, M., Safavi, F., Zhang, G.-X., Dittel, B. N., & Rostami, A. (2011) · Nature Immunology · doi:10.1038/ni.2031 · Cited by 1,071
The myeloid cells of the central nervous system parenchyma
Ransohoff, R. M., & Cardona, A. E. (2010) · Nature · doi:10.1038/nature09615 · Cited by 804 · cited 2×
“DCs and macrophages are key antigen-presenting cells (APCs) during the pathogenesis of EAE [10,22,27].”
BackgroundJäger, A., Dardalhon, V., Sobel, R. A., Bettelli, E., & Kuchroo, V. K. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901906 · Cited by 783 · cited 1×
“The most well-known advocating evidence of this statement is the development of Th1/Th17 CNS-infiltrating cells in the CNS and the causal exacerbation of EAE progression due to their presence [13].”
BackgroundAnti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control
Lee, Y.-S., & Jun, H.-S. (2016) · Mediators of Inflammation · doi:10.1155/2016/3094642 · Cited by 530 · cited 1×
“Despite its original purpose for blood glucose control, the role of GLP-1 RA on immune modulation has been increasingly recognized [28].”
BackgroundTh17 cells give rise to Th1 cells that are required for the pathogenesis of colitis
Harbour, S. N., Maynard, C. L., Zindl, C. L., Schoeb, T. R., & Weaver, C. T. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1415675112 · Cited by 427
Lee, Y.-S., Park, M.-S., Choung, J.-S., Kim, S.-S., Oh, H.-H., Choi, C.-S., Ha, S.-Y., Kang, Y., Kim, Y., & Jun, H.-S. (2012) · Diabetologia · doi:10.1007/s00125-012-2592-3 · Cited by 319 · cited 1×
“Similar with our results, treatment of GLP-1 RA [33] or DPP4 inhibitors [34] reduces adipose macrophage infiltration in an obese mice model.”
ResultYusta, B., Baggio, L. L., Koehler, J., Holland, D., Cao, X., Pinnell, L. J., Johnson-Henry, K. C., Yeung, W., Surette, M. G., Bang, K. W. A., et al. (2015) · Diabetes · doi:10.2337/db14-1577 · Cited by 282 · cited 1×
“In addition, activation of the GLP-1 receptor on the intestinal intraepithelial lymphocyte suppresses the pro-inflammatory cytokine expression [26].”
BackgroundT-bet is required for optimal proinflammatory CD4+ T-cell trafficking
Lord, G. M. (2005) · Blood · doi:10.1182/blood-2005-04-1393 · Cited by 270
T cell responses in the central nervous system
Korn, T., & Kallies, A. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.144 · Cited by 268 · cited 2×
“DCs and macrophages are key antigen-presenting cells (APCs) during the pathogenesis of EAE [10,22,27].”
BackgroundKim, S., Moon, M., & Park, S. (2009) · Journal of Endocrinology · doi:10.1677/joe-09-0132 · Cited by 263 · cited 1×
“Accumulating data revealed that the administration of GLP-1 receptor agonist (GLP-1 RA) not only alleviates traumatic or ischemic brain damage [2,3] but also ameliorates neurodegenerative diseases demonstrated in Alzheimer’s disease (AD) and Parkinson’s disease mice models [4,5] through reduced neuronal cell death and…”
BackgroundGlucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation
Shiraishi, D., Fujiwara, Y., Komohara, Y., Mizuta, H., & Takeya, M. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.07.086 · Cited by 208
Hadjiyanni, I., Siminovitch, K. A., Danska, J. S., & Drucker, D. J. (2010) · Diabetologia · doi:10.1007/s00125-009-1643-x · Cited by 166 · cited 3×
“Glp1 knockout mice exhibited hyper-proliferative lymphocytes in response to mitogenic stimuli and a lower percentage of peripheral regulatory T cells [24].”
BackgroundInfluentialDobrian, A. D., Ma, Q., Lindsay, J. W., Leone, K. A., Ma, K., Coben, J., Galkina, E. V., & Nadler, J. L. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00463.2010 · Cited by 166 · cited 1×
“Similar with our results, treatment of GLP-1 RA [33] or DPP4 inhibitors [34] reduces adipose macrophage infiltration in an obese mice model.”
ResultBerard, J. L., Wolak, K., Fournier, S., & David, S. (2010) · Glia · doi:10.1002/glia.20935 · Cited by 147 · cited 1×
“The disease course of this model mainly follows a relapse-remitting or chronic disease course during the 40 days of observation [38].”
BackgroundCCR2 defines in vivo development and homing of IL-23-driven GM-CSF-producing Th17 cells
Kara, E. E., McKenzie, D. R., Bastow, C. R., Gregor, C. E., Fenix, K. A., Ogunniyi, A. D., Paton, J. C., Mack, M., Pombal, D. R., Seillet, C., et al. (2015) · Nature Communications · doi:10.1038/ncomms9644 · Cited by 136
Dai, Y., Dai, D., Wang, X., Ding, Z., & Mehta, J. L. (2014) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-014-6539-4 · Cited by 116
Steven, S., Hausding, M., Kröller-Schön, S., Mader, M., Mikhed, Y., Stamm, P., Zinßius, E., Pfeffer, A., Welschof, P., Agdauletova, S., et al. (2015) · Basic Research in Cardiology · doi:10.1007/s00395-015-0465-x · Cited by 114 · cited 1×
“Treatment of DPP4 inhibitor (gliptin) decreases dendritic cell maturation upon LPS-induced endotoxemia [37].”
BackgroundCharacterization of brain lesions in a mouse model of progressive multiple sclerosis
Levy, H., Assaf, Y., & Frenkel, D. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.08.017 · Cited by 50 · cited 1×
“Notably, establishing of EAE on the non-obese diabetic (NOD) background would lead to the development of relapse-remitting to a chronic progressive stage from 20 to 70 days after MOG immunization [39], which is considered closer to the clinical disease course of MS patients [40].”
Background
Cited by
The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists
Bendotti, G., Montefusco, L., Lunati, M. E., Usuelli, V., Pastore, I., Lazzaroni, E., Assi, E., Seelam, A. J., El Essawy, B., Jang, J., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106320 · Cited by 406
Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases
Diz-Chaves, Y., Mastoor, Z., Spuch, C., González-Matías, L. C., & Mallo, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179583 · Cited by 148
GLP-1 receptor agonist as a modulator of innate immunity
Chen, J., Mei, A., Wei, Y., Li, C., Qian, H., Min, X., Yang, H., Dong, L., Rao, X., & Zhong, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.997578 · Cited by 120
Pang, J., Feng, J. N., Ling, W., & Jin, T. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.06.003 · Cited by 52
Sango, K., Takaku, S., Tsukamoto, M., Niimi, N., & Yako, H. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.950623 · Cited by 30
“Likewise, subcutaneous dulaglutide injection (180 μg/kg/twice per week) to EAE mice attenuated the clinical manifestations and histopathological outcomes (lymphocyte infiltration, vacuolar degeneration, and neuronal demyelination), as well as decreased incidences of encephalitogenic Th1/Th17 cells and Th1 granulocytem…”
Background
Metadata
- Authors
- Chiou, H.-Y. C., Lin, M.-W., Hsiao, P.-J., Chen, C.-L., Chiao, S., Lin, T.-Y., Chen, Y.-C., Wu, D.-C., & Lin, M.-H.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-03-29
- Volume
- 20
- Issue
- 7
- Pages
- 1584
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2931543462
- Cited by
- 47
- References
- 22
- FWCI
- 2.19
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.